-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, NBMAm+lLlbbFH+1KgexqS3RckzBn5ZkjcsDdr5eDHVitY+LAQ+a67cryVjvP4SMT hPxloyT1HpLXnpgixwQ0Fw== 0000950116-01-500708.txt : 20010816 0000950116-01-500708.hdr.sgml : 20010816 ACCESSION NUMBER: 0000950116-01-500708 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20010807 ITEM INFORMATION: Other events ITEM INFORMATION: Financial statements and exhibits FILED AS OF DATE: 20010815 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GENEREX BIOTECHNOLOGY CORP CENTRAL INDEX KEY: 0001059784 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 820490211 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-25169 FILM NUMBER: 1715254 BUSINESS ADDRESS: STREET 1: 33 HARBOUR SQ STREET 2: STE 202 CITY: TORONTO ONTARIO CANA STATE: A1 BUSINESS PHONE: 4163642551 MAIL ADDRESS: STREET 1: 33 HARBOUR SQ STREET 2: STE 202 CITY: TORONTO ONTARIO M5J STATE: A1 8-K 1 eightk.txt EIGHTK.TXT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 7, 2001 --------------- Generex Biotechnology Corporation ----------------------------------------------------------------------- (Exact name of registrant as specified in its charter) Delaware 000-25169 82-049021 - ---------------------------- ------------ ------------------- (State or other jurisdiction (Commission (IRS Employer of Incorporation) File Number) Identification No.) 33 Harbor Square, Suite 202, Toronto, Ontario Canada M5J 2G2 - -------------------------------------------------------------------------------- (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code 416/364-2551 ---------------- ------------------------------------------------------------------- (Former name or former address, if changed since last report) Item 5. Other Items. Termination of Equity Draw Down Facility On August 14, 2000 the Company entered into a common stock purchase agreement with Tradersbloom Limited, a British Virgin Islands corporation ("Tradersbloom"). The common stock purchase agreement established what is sometimes referred to as an equity draw down facility. Pursuant to the common stock purchase agreement, the Company had the option to sell shares of the Company's common stock to Tradersbloom. The Company could sell up to $50,000,000 of common stock to Tradersbloom until October 31, 2001, at which time the common stock purchase agreement would terminate. On August 7, 2001, the Company entered into a termination agreement with Tradersbloom, pursuant to which the parties terminated the equity draw down facility. The Company paid $245,000 to satisfy its obligations to Tradersbloom under the equity draw down facility. Neither the Company nor Tradersbloom has any further rights or obligations under the equity draw down facility. Item 7. Financial Statements and Exhibits. None. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GENEREX BIOTECHNOLOGY CORPORATION Dated: August 15, 2001 By: /s/ E. Mark Perri --------------- ------------------------------------ E. Mark Perri, Chairman and CFO -----END PRIVACY-ENHANCED MESSAGE-----